CVS earnings show a turnaround in action as the stock rebounds

Core Viewpoint - CVS stock has risen 40% over the last 12 months, significantly outperforming major indexes and achieving returns comparable to Nvidia in percentage terms, despite being a pharmacy chain [1] Group 1: Stock Performance and Market Perception - CVS was previously viewed as a problem stock, with concerns about rising medical costs, structural issues, and the effectiveness of its healthcare model [1][2] - At its lowest point, CVS stock traded at a steep discount, reflecting market skepticism about the company's future [2] Group 2: Financial Results - For Q4, CVS reported revenue of $105.7 billion, an increase of 8.2% year over year, while full-year 2025 revenue surpassed $400 billion, marking a new record [3] - Adjusted earnings per share rose to $6.75 for the year, up from $5.42 in 2024, and operating cash flow exceeded $10 billion [3] Group 3: Segment Performance - Growth was observed across all major segments: insurance, pharmacy services, and retail pharmacy [3] - Aetna's results were mixed, with some trends improving while others remained problematic, reflecting the complexities of the healthcare landscape [4][5] - CVS's pharmacy middleman and health services arm showed steady performance, while retail pharmacy volumes surged nearly 20% in the quarter, indicating the company's scale may be advantageous [6] Group 4: Strategic Goals and Industry Context - Management aims to position CVS as "America's most trusted health care company," though the claim may be viewed skeptically given the adversarial nature of the U.S. healthcare system [7] - The company's turnaround suggests it is navigating the complexities of the healthcare environment more effectively, though the effectiveness of scale and vertical integration remains uncertain [8]